UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from_______________________to_______________________ Commission File No. 1-32525 AMERIPRISE FINANCIAL, INC. (Exact name of registrant as specified in its charter) Delaware 13-31806 ...

Exhibit 99.1 Inseego Reports Fourth Quarter and Full-Year 2025 Financial Results Q4 2025 revenue of $48.4 million, third consecutive quarter of sequential growth Q4 2025 Adjusted EBITDA* of $6.0 million and 12.4% margin and GAAP Net Income of $0.5 million Eliminated all outstanding Preferred Stock at 38% Discount SAN DIEGO—February 19, 2026—Inseego Corp. (Nasdaq: INSG) (the "Company"), a global leader in 5G mobile broadband and 5G fixed wireless access (FWA) solutions, today reported its results for the fou ...

Financial Performance and Risks - The company has incurred losses each year since its inception in October 2007, with an accumulated deficit of $946.9 million as of December 31, 2025[126]. - The company's ability to achieve cash flow positivity is heavily dependent on the successful commercialization of IBSRELA and XPHOZAH, as well as potential pipeline expansions[128]. - Future funding requirements will be influenced by the ability to generate revenue from IBSRELA and XPHOZAH, as well as ongoing clinical trials and development costs[133]. - The overall commercial success of IBSRELA and XPHOZAH will depend on market acceptance, reimbursement levels, and competition from alternative treatments[137]. - The company faces risks related to maintaining adequate third-party reimbursement for both IBSRELA and XPHOZAH, which could affect revenue generation[141]. - The effectiveness of IBSRELA and XPHOZAH as treatments will be critical for securing market share and achieving financial goals[140]. - The company may require additional financing to support the growth of IBSRELA and XPHOZAH and to build its product pipeline[133]. - The company faces substantial liabilities from potential product liability lawsuits related to IBSRELA and XPHOZAH, which could limit commercialization efforts[186]. - The company maintains product liability insurance, but claims may exceed coverage limits, leading to significant financial burdens[187]. Commercialization and Market Dynamics - The commercialization of IBSRELA began in March 2022, and XPHOZAH was launched in November 2023, targeting specific patient populations[126]. - The elimination of Medicare Part D coverage for XPHOZAH on January 1, 2025, is expected to negatively impact revenue growth and market acceptance[130]. - The lack of Medicare Part D coverage for XPHOZAH is anticipated to lead to a materially lower pace of revenue growth compared to prior expectations[145]. - The commercial success of XPHOZAH may be limited by undesirable side effects or other properties that could affect market acceptance[146]. - Third-party payor coverage and reimbursement for IBSRELA and XPHOZAH are uncertain, which could limit marketing capabilities and revenue generation[150]. - The pricing, coverage, and reimbursement for IBSRELA and XPHOZAH must be adequate to support a commercial infrastructure, as inadequate reimbursement could hinder successful commercialization[150]. - International operations face extensive governmental price controls, which may pressure pricing and usage of IBSRELA and XPHOZAH, potentially leading to insufficient revenue generation[152]. - Increasing efforts by payors to cap healthcare costs may limit coverage and reimbursement levels for newly approved products, impacting revenue potential[153]. - The company relies on third-party manufacturers for IBSRELA and XPHOZAH, and any disruptions in their ability to meet regulatory requirements could materially harm commercialization efforts[154]. Drug Development and Regulatory Challenges - The drug development process is long and uncertain, with significant risks involved in obtaining regulatory approval for product candidates[160]. - Ongoing development activities may face delays due to healthcare staffing shortages and increased competition for clinical trial sites, potentially impacting timelines and budgets[164]. - The drug development process is lengthy, with only a small percentage of drugs successfully completing FDA approval, which could hinder commercialization efforts[167]. - The company relies on single-source manufacturers for critical components, exposing it to supply chain risks, including delivery failures and drug shortages[169]. - The FDA's ability to review and process regulatory submissions may be hindered by funding shortages or global health concerns, potentially delaying drug approvals[231]. - Regulatory authorities can impose sanctions for non-compliance, including withdrawal of approvals or suspension of production, which could materially harm the company's business[236]. - Delays or failures in obtaining regulatory approvals could negatively impact the company's ability to commercialize products, affecting financial results[245]. Competition and Market Position - Competition for IBSRELA includes established products like Linzess and Amitiza, as well as generic alternatives, which may impact market share[176]. - XPHOZAH faces competition from various phosphate binders, including generics, which could affect its market positioning[177]. - The biotechnology industry is highly competitive, with larger companies having more resources, which may hinder the company's ability to compete effectively[180]. - The company may engage in strategic transactions, such as acquisitions or partnerships, which could increase expenses and distract management from core operations[182]. Compliance and Legal Risks - The company must ensure compliance with Good Clinical Practices (GCPs) and Good Laboratory Practices (GLPs) in clinical trials, as non-compliance could lead to unreliable data and additional regulatory hurdles[207]. - The company is subject to evolving data protection regulations, including the GDPR, which imposes fines of up to €20 million or 4% of annual global revenue for non-compliance[194]. - Non-compliance with data protection laws could result in negative publicity, government investigations, and financial penalties, adversely affecting operations and financial performance[190]. - The company is subject to extensive regulations regarding the promotion of its products, and failure to comply could lead to substantial fines or sanctions[239]. - Investigations into the promotion of products for unapproved uses could result in civil or criminal penalties, adversely affecting the company's financial prospects[240]. - The company must report adverse medical events related to its products, and failure to do so could lead to significant sanctions[242]. Intellectual Property and Trade Secrets - The company relies on a combination of legal protections, including patents and trade secrets, to safeguard its intellectual property, but these measures provide limited protection against competitors[260]. - There is a risk that the company may fail to obtain or enforce necessary intellectual property rights, which could negatively impact its competitive position and lead to significant expenses[261]. - The company has a portfolio of issued and pending patent applications, but there is a possibility of failing to identify patentable aspects of inventions, which could hinder future patent protection[262]. - The enforceability of patents in the biotechnology and pharmaceutical fields is uncertain, and challenges to patent validity could adversely affect the company's ability to compete effectively[274]. - The company may face third-party claims alleging infringement of intellectual property rights, which could result in costly litigation and impact product development[269]. Financial Position and Market Conditions - As of December 31, 2025, the company had cash, cash equivalents, and short-term investments totaling $264.7 million, including high-quality fixed income instruments[412]. - The principal outstanding under the 2022 Loan Agreement is $200.0 million, subject to a variable interest rate that could increase interest expenses by approximately $1.8 million with a 100 basis points rise in the one-month CME Term SOFR[413]. - The company maintains its excess cash in money market funds and short-term debt securities to minimize interest rate risk, believing that a 10% movement in market interest rates would not significantly impact the portfolio's total value[412]. - The company is exposed to foreign currency risk due to transactions in currencies other than the U.S. dollar, primarily Swiss francs, Japanese yen, and the Euro[414]. - The company does not intend to pay dividends on its common stock for the foreseeable future, which means stockholders' returns will depend on the appreciation of the stock price[313].

Financial Performance and Risks - The company's backlog as of December 31, 2025, was $11.94 billion, indicating potential revenue yet to be recognized[74] - Approximately 5.0% of the company's revenue for the year ended December 31, 2025, was attributable to projects in the government sector, highlighting dependency on government spending[72] - One customer represented approximately 12.8% of the company's consolidated revenue in 2025, indicating a risk of revenue concentration[75] - Rising inflation has increased costs for labor, materials, and services, which may adversely affect profitability and cash flows[76] - The company is exposed to cost overruns in contracts, which could lead to reduced profits or losses if costs exceed estimates[73] - Delays and defaults in customer payments could materially affect the company's financial condition and cash flows[90] - The company operates in a highly competitive market, which may pressure profit margins and market share[77] - The company has experienced significant fluctuations in its common stock price, which may continue and could result in losses for shareholders[131] - The company’s financial results are subject to review by taxing authorities, and outcomes differing from recorded liabilities could adversely affect financial condition[128] - Warranty claims, while historically not material, could require the company to incur costs for repairs or replacements, adversely affecting financial results[117] - The company faces potential legal claims that could reduce profitability and liquidity, impacting financial condition and cash flows[116] - Tax matters, including changes in corporate tax laws, could materially impact the company's financial results and condition[127] Operational Challenges - The company may face challenges in integrating future acquisitions, which could impact financial performance and operational efficiency[78] - Labor shortages and increased labor costs from third parties could adversely impact the company's results of operations[83] - The company faces challenges in attracting and retaining qualified personnel, which could increase labor costs and affect operational efficiency[97] - Growth may impose additional responsibilities on senior management, and failure to manage growth effectively could hinder operational expansion[98] - The decentralized decision-making structure may slow the company's response to operational issues and compliance risks[99][100] - Ineffective management of backlog and operational costs could strain resources and hinder revenue growth[101] - The company’s workforce utilization directly impacts profitability; underutilization could lead to lower gross margins[114] Regulatory and Compliance Risks - The company is subject to various environmental regulations, including the federal Clean Air Act, which could impose significant additional costs and reduce profits[122] - The company may face challenges in obtaining necessary insurance coverage, which could increase overall risk exposure and limit project opportunities[110][112] - Non-compliance with credit agreement covenants could lead to default, impacting the company's ability to operate and service debt obligations[113] - The company has 190 locations across 27 states, exposing it to various state and local regulations, which could increase costs and negatively impact financial condition[120] - The company may face increased regulatory scrutiny and compliance costs related to data privacy and cybersecurity threats[109] Market and Economic Conditions - Political and economic uncertainties, including inflation and supply chain disruptions, may constrain customer spending and impact the company's financial condition[95] - Changes in U.S. foreign trade policies could lead to additional trade barriers, negatively impacting the company's ability to purchase materials and supplies[126] - The company is susceptible to adverse weather conditions, which may lead to service curtailment, operational suspension, and potential liability for liquidated damages[92] - Future climate change poses physical and financial risks, including increased extreme weather events that could delay or cancel projects[93] - Ongoing political and economic uncertainties, including inflation and supply chain disruptions, may hinder the company's ability to forecast and plan business activities[95] Internal Controls and Reporting - The company plans to maintain and strengthen internal controls to enhance the effectiveness of financial reporting[141] - The company’s internal control over financial reporting is assessed annually, and findings of inadequacy could reduce investor confidence in financial information[139] - Changes in accounting rules could adversely affect reported financial results and require significant changes to systems and processes[142] - Any deficiencies in internal control could lead to a material weakness, potentially resulting in misstatements of financial statements and loss of investor confidence[140] Cybersecurity and IT Risks - Cybersecurity risks threaten the integrity of IT systems, potentially leading to financial losses and operational disruptions[102][103] - IT system failures and cybersecurity breaches could disrupt operations and lead to significant financial losses[102][107]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-43039 BLACK SPADE ACQUISITION III CO (Exact Name of Registrant as Specified in Its Charter) Cayman Islands N/A (State ...

Revenue Growth - Full-year revenue for 2025 was $756.0 million, an 11% increase year-over-year, driven by subscription initiatives and the Formation Nation acquisition[6] - Subscription revenue for 2025 reached $492.5 million, up 13% year-over-year, reflecting a focus on higher-value customers[6] - Fourth quarter revenue was $190.3 million, an 18% increase year-over-year, with subscription revenue at $130.9 million, up 20%[7] - Revenue for the year ended December 31, 2025, was $756,043,000, representing a 10.9% increase from $681,881,000 in 2024[30] - The first quarter of 2026 revenue is expected to be between $200 million and $203 million, representing a 10% year-over-year growth at the midpoint[9] Profitability Metrics - Adjusted EBITDA for 2025 was $172.2 million, representing a 16% increase year-over-year, with an Adjusted EBITDA margin of 23%[6][8] - Adjusted EBITDA for the year ended December 31, 2025, was $172,193,000, compared to $148,114,000 in 2024, reflecting a growth of 16.2%[34] - The company reported a net income margin of 2% for the year ended December 31, 2025, down from 4% in 2024[34] - For the year ended December 31, 2025, the company reported a Non-GAAP net income of $114,249,000, compared to $99,451,000 for 2024, representing a 14.3% increase[36] - The Non-GAAP net income margin for 2025 was 15%, consistent with 2024, while the net income margin decreased from 4% in 2024 to 2% in 2025[36] Cash Flow and Financial Position - The company reported record free cash flow of $147.9 million for 2025, up 48% year-over-year[6] - Cash and cash equivalents at the end of the period increased to $203,100,000 from $142,064,000 at the beginning of the period, marking a rise of 43%[31] - Net cash provided by operating activities for the year ended December 31, 2025, was $178,197,000, compared to $135,639,000 in 2024, reflecting a 31.4% increase[39] - LegalZoom's cash and cash equivalents stood at $203.1 million as of December 31, 2025, with no debt outstanding[6] Shareholder Returns - A $100 million increase to the share repurchase authorization was announced, underscoring confidence in the business and commitment to shareholder returns[4] Future Outlook - LegalZoom expects 2026 revenue to be in the range of $805 million to $825 million, reflecting an 8% year-over-year growth at the midpoint[16] - The company anticipates Adjusted EBITDA for 2026 to be between $190 million and $200 million, indicating a 13% year-over-year growth at the midpoint[16] Expenses and Liabilities - Total liabilities increased to $339,640,000 in 2025 from $280,626,000 in 2024, indicating a rise of 20.9%[28] - Stock-based compensation expense for the year ended December 31, 2025, was $113,708,000, significantly higher than $71,510,000 in 2024, an increase of 58.9%[32] - The company incurred restructuring costs related to the reduction of U.S. headcount for both 2024 and 2025[37] Net Income - Net income for the year ended December 31, 2025, was $15,427,000, a decrease of 48.6% compared to $29,963,000 in 2024[30] - The diluted Non-GAAP net income per share for 2025 was $0.62, compared to $0.54 for 2024, representing a 14.8% increase[38] - The weighted-average shares used to compute diluted Non-GAAP net income per share increased from 182,865 in 2024 to 184,690 in 2025[38]

Financial Investments - As of December 31, 2025, eBay's total cash and investments included approximately $2.9 billion in corporate bonds, commercial paper, and government and agency securities, representing about 42% of total cash and investments [298]. - eBay's equity investments totaled $929 million as of December 31, 2025, accounting for approximately 14% of total cash and investments, primarily related to its investment in Adevinta [300]. - A hypothetical 1% increase in interest rates would have resulted in a decrease in the fair value of eBay's investments by $30 million as of December 31, 2025 [298]. - eBay's investment strategy aims to preserve principal while improving yields, maintaining a diverse portfolio of asset types [297]. Human Capital Management - eBay employs approximately 12,300 people globally, with around 7,200 located in the United States, reflecting its commitment to human capital management [51]. - The company emphasizes the importance of ethics and integrity in its culture, promoting open communication and ethical decision-making among employees [55]. Foreign Exchange Management - eBay's foreign exchange exposure management program aims to mitigate the impact of currency fluctuations on its financial results through the use of foreign currency exchange contracts [302]. - The fair value of foreign exchange contracts designated as cash flow hedges was $15 million, with a potential loss of $89 million from a hypothetical 20% adverse change in foreign exchange rates [306]. - The company assessed historical trends in currency exchange rates and identified a potential adverse change of 20% for all currencies in the near term [308]. - The impact of these currency changes, considering foreign exchange forwards, would have resulted in an immaterial adverse effect on income before income taxes as of December 31, 2025 [308]. Technology and Innovation - eBay's technology infrastructure supports scalable operations and enhances customer experiences through investments in proprietary computing infrastructure and strategic partnerships [45]. - The company is focused on modernizing its Marketplace platforms using advanced technologies like AI to create personalized shopping experiences [46].

Exhibit 99.1 Investor Contact: Media Contact: Susannah Livingston media@sprouts.com (602) 682-1584 susannahlivingston@sprouts.com Leverage and Liquidity in 2025: First Quarter and Full-Year 2026 Outlook "While we were pleased with our 2025 results and remain confident in our long-term growth, we expect challenges in 2026, especially in the first half due to strong prior year comparisons and a dynamic macro environment," said Curtis Valentine, chief financial officer of Sprouts Farmers Market. The following ...

Rimini Street Announces Fiscal Fourth Quarter and Annual 2025 Financial and Operating Results page 1 Exhibit 99.1 FOR IMMEDIATE RELEASE Rimini Street Announces Fiscal Fourth Quarter and Annual 2025 Financial and Operating Results Fourth Quarter and Full Year 2025 Financial Highlights Include: Remaining Performance Obligations (RPO) of $652.9 million, up 11.1% from the prior year Adjusted Calculated Billings, full year 2025, up 4.2% from the prior year Adjusted Annualized Recurring Revenue (ARR) up 3.1% from ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________. Commission file number 001-36108 ONE Gas, Inc. | (Exact name of registrant as specified in its charter) | | --- | Oklahoma 46-3561936 Registrant's ...